Glenmark Pharma launches Empagliflozin in India

Empagliflozin, a well-known SGLT2 inhibitor, has been introduced in India by Glenmark Pharmaceuticals Ltd. (Glenmark), a multinational pharmaceutical business that prioritizes research. Along with its fixed-dose combinations (FDCs), Glempa-L (empagliflozin 10/25 mg + linagliptin 5 mg) and Glempa-M (empagliflozin 12.5 mg + metformin 500/1000 mg), the medication was first marketed under the trade name Glempa (empagliflozin 10/25 mg).

These drugs aim to lower cardiovascular outcomes in T2DM patients with CV risk and enhance glycaemic management in individuals with T2DM. Empagliflozin is a well-known medication used worldwide to treat heart failure, type 2 diabetes, and type 2 diabetes with established cardiovascular disease (CVD). It has several advantages, including cardiovascular and renal safety 6. Empagliflozin was shown to reduce major cardiovascular events by 14% in the EMPA-REG clinical trial, making it a noteworthy improvement for T2DM patients with elevated cardiovascular risks.

Studies have shown that empagliflozin and its combinations are effective in addition to having cardiovascular advantages. According to a 24-week study, taking 500/1000 mg of metformin and 12.5 mg of empagliflozin twice a day helped people with type 2 diabetes lose weight (3 to 3.8 kg), lower their fasting blood sugar (43.2 to 50.4 mg/dL), and lower their blood sugar levels (HbA1c by 1.9% to 2.1%). All of these effects were highly significant.

An additional 24-week research demonstrated that the combination of empagliflozin (10/25 mg) and linagliptin (5 mg) was more effective than either medication alone in lowering patients' HbA1c (by 1.24%), weight (by 2 to 2.7 kg), and fasting blood sugar (by 28.21 to 29.55 mg/dL).